Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients
| Autor: | Keren Tsaraf, Yaniv Lustig, Einav G Levin, Itzchak Levy, Yana Davidov, Mariya Likhter, Orna Mor, Oranit Cohen-Ezra, Galia Rahav, Ziv Ben Ari, Gil Ben Yakov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty COVID-19 Vaccines medicine.medical_treatment Liver transplantation Antibodies Viral Gastroenterology Immune system Internal medicine medicine Humans RNA Messenger Adverse effect BNT162 Vaccine Vaccines Synthetic Transplantation Hepatology biology SARS-CoV-2 business.industry Immunogenicity Antibody titer COVID-19 Immunosuppression Original Articles Transplant Recipients Liver Transplantation Vaccination biology.protein Female Original Article Surgery mRNA Vaccines Antibody business |
| Zdroj: | Liver Transplantation |
| ISSN: | 1527-6473 1527-6465 |
| Popis: | The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients. The immune responses of 76 LT recipients receiving 2 doses of the vaccine were compared with those of 174 age‐matched immunocompetent controls. Postvaccination immunoglobulin G (IgG) antibodies against the receptor‐binding domain (RBD) of SARS‐CoV‐2 and neutralizing antibodies (NA) to the BNT162b2 mRNA vaccine were determined at least 14 days after the second dose of the vaccine. IgG antibody titers ≥1.1 were defined as positive antibodies. Adverse effects were monitored during the study period. Following administration of the second dose, transplant recipients showed reduced immune responses compared with controls (72% versus 94.2%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text